Medicines Formulary

Medicines A–Z

V

Drug name	NICE TAs	Comments
Vemurafenib tablets	TA269 - Vemurafenib for treating locally advanced or metastatic BRAF V600 mutation-positive malignant melanoma	National CDF list
Venetoclax (Venclyxto®)	TA487 - Venetoclax for treating chronic lymphocytic leukaemia TA561 - Venetoclax with rituximab for previously treated chronic lymphocytic leukaemia TA663 - Venetoclax with obinutuzumab for untreated chronic lymphocytic leukaemia TA796: Venetoclax for treating chronic lymphocytic leukaemia	For hospital use only And azacitidine for relapsed or refractory AML
Venlafaxine M/R capsules		Specialist initiation only
Venlafaxine tablets		Specialist initiation only
Verapamil M/R tablets		Brand rationalisation, APC preferred brands: Univer Capsules, Securon SR Tablets
Verapamil tablets		Brand rationalisation, APC preferred brands: Univer Capsules, Securon SR Tablets
Verteprofin (Visudyne)	TA68 - Guidance on the use of photodynamic therapy for age-related macular degeneration
Vigabatrin tablets		ESCA
Vinblastine injection		For hospital use only
Vincristine injection		For hospital use only

Drug status key

Formulary drugs are allocated a traffic light status. This provides guidance on where clinical and prescribing responsibilities lie in regard to the initiation and maintenance of prescribing.

Grey

Positive NICE TA and/or awaiting local clarification on place in therapy. Please contact your medicines optimisation team for more information.

Red

Initiation and maintenance of prescribing by specialists only.

Amber

Initiation and maintenance of prescribing by specialists and transfer to primary care prescribing when appropriate, or in primary care following a specialists recommendation. Prior to initiation some medicines may require committee agreement or a framework to support safe transfer and maintenance.

Green

Initiation and maintenance of prescribing by specialists, GPs and other qualified clinicians.

Blue

Under review at University Hospitals Birmingham NHS Foundation Trust.